ALK and anaplastic large cell lymphoma: Using an IFN-γ ELISPOT assay, the authors showed that two in silico selected DRB1-restricted ALK-derived peptides were immunogenic in ALK-positive ALCL patients but not in ALK-negative ALCL patients or healthy controls.